119 related articles for article (PubMed ID: 6470756)
1. Acivicin: a new glutamine antagonist in clinical trials.
O'Dwyer PJ; Alonso MT; Leyland-Jones B
J Clin Oncol; 1984 Sep; 2(9):1064-71. PubMed ID: 6470756
[No Abstract] [Full Text] [Related]
2. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
3. Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.
McGovren JP; Stewart JC; Elfring GL; Smith RB; Soares N; Wood JH; Poplack DG; Von Hoff DD
Cancer Treat Rep; 1982 Jun; 66(6):1333-41. PubMed ID: 7083237
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.
Earhart RH; Koeller JM; Davis TE; Borden EC; McGovren JP; Davis HL; Tormey DC
Cancer Treat Rep; 1983; 67(7-8):683-92. PubMed ID: 6871883
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.
McGovren JP; Pratt EA; Belt RJ; Taylor SA; Benjamin RS; Ardalan B; Ohnuma T
Cancer Res; 1985 Sep; 45(9):4460-3. PubMed ID: 3896481
[TBL] [Abstract][Full Text] [Related]
6. Acivicin reduces tumor growth during total parenteral nutrition (TPN).
Chance WT; Cao L; Nelson JL; Foley-Nelson T; Fischer JE
Surgery; 1987 Aug; 102(2):386-94. PubMed ID: 3112985
[TBL] [Abstract][Full Text] [Related]
7. Response of tumor and host to hyperalimentation and antiglutamine treatments.
Chance WT; Cao LQ; Fischer JE
JPEN J Parenter Enteral Nutr; 1990; 14(2):122-8. PubMed ID: 2112618
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Jayaram HN; Ardalan B; Deas M; Johnson RK
Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of acivicin in patients with advanced cancer.
Sridhar KS; Ohnuma T; Chahinian AP; Holland JF
Cancer Treat Rep; 1983; 67(7-8):701-3. PubMed ID: 6871885
[No Abstract] [Full Text] [Related]
10. Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
Huber KR; Mayer EP; Mitchell DF; Roberts J
Br J Cancer; 1987 Jun; 55(6):653-6. PubMed ID: 3620309
[No Abstract] [Full Text] [Related]
11. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
12. Acivicin in 1985.
Earhart RH; Neil GL
Adv Enzyme Regul; 1985; 24():179-205. PubMed ID: 3915184
[TBL] [Abstract][Full Text] [Related]
13. Enzyme targets of antiglutamine agents in cancer chemotherapy.
Prajda N
Adv Enzyme Regul; 1985; 24():207-23. PubMed ID: 2424283
[TBL] [Abstract][Full Text] [Related]
14. Multi-enzyme-targeted chemotherapy by acivicin and actinomycin.
Weber G; Prajda N; Lui MS; Denton JE; Aoki T; Sebolt J; Zhen YS; Burt ME; Faderan MA; Reardon MA
Adv Enzyme Regul; 1982; 20():75-96. PubMed ID: 6180609
[TBL] [Abstract][Full Text] [Related]
15. Sex- and age-related mouse toxicity and disposition of the amino acid antitumor agent, acivicin.
McGovren JP; Neil GL; Chan PJ; Stewart JC
J Pharmacol Exp Ther; 1981 Mar; 216(3):433-40. PubMed ID: 7205622
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
[No Abstract] [Full Text] [Related]
17. Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture.
Williams MG; Earhart RH; Bailey H; McGovren JP
Cancer Res; 1990 Sep; 50(17):5475-80. PubMed ID: 2386952
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological study of acivicin by 24-hour continuous infusion.
Weiss GR; McGovren JP; Schade D; Kufe DW
Cancer Res; 1982 Sep; 42(9):3892-5. PubMed ID: 7105049
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Greco A; Prestridge K; Johnson R
Cancer Treat Rep; 1986 Aug; 70(8):1031-2. PubMed ID: 3524833
[No Abstract] [Full Text] [Related]
20. Reduction of tumor growth following treatment with a glutamine antimetabolite.
Chance WT; Cao L; Kim MW; Nelson JL; Fischer JE
Life Sci; 1988; 42(1):87-94. PubMed ID: 3336272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
